Detection of E119V and E119I Mutations in Influenza A (H3N2) Viruses Isolated from an Immunocompromised Patient: Challenges in Diagnosis of Oseltamivir Resistance

被引:75
作者
Okomo-Adhiambo, Margaret [1 ]
Demmler-Harrison, Gail J. [2 ,3 ,4 ]
Deyde, Varough M. [1 ]
Sheu, Tiffany G. [1 ]
Xu, Xiyan [1 ]
Klimov, Alexander I. [1 ]
Gubareva, Larisa V. [1 ]
机构
[1] Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA
[2] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[4] Texas Childrens Hosp, Diagnost Virol Lab, Houston, TX 77030 USA
关键词
NEURAMINIDASE INHIBITORS; SUSCEPTIBILITY; ZANAMIVIR; SURVEILLANCE; WORLDWIDE; SELECTION; ASSAY;
D O I
10.1128/AAC.01608-09
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The clinical use of the neuraminidase inhibitor (NAI) oseltamivir is associated with the emergence of drug resistance resulting from subtype-specific neuraminidase (NA) mutations. The influenza A/Texas/12/2007 (H3N2) virus isolated from an oseltamivir-treated immunocompromised patient exhibited reduced susceptibility to oseltamivir in the chemiluminescent neuraminidase inhibition (NI) assay (similar to 60-fold increase in its 50% inhibitory concentration [IC50] compared to that for a control virus). When further propagated in cell culture, the isolate maintained reduced susceptibility to oseltamivir in both chemiluminescent and fluorescent NI assays (similar to 50-and 350-fold increases in IC50, respectively). Sequencing analysis of the isolate revealed a mix of nucleotides coding for amino acids at position 119 of the NA [E119(V/I)]. Plaque purification of the isolate yielded E119V and E119I variants, both exhibiting reduced susceptibility to oseltamivir. The E119I variant also showed decreased susceptibility to zanamivir and the investigational NAIs peramivir and A-315675. The emergence of E119V variants in oseltamivir-treated patients has been previously reported; however, the E119I mutation detected here is a novel one which reduces susceptibility to several NAIs. Both mutations were not detected in unpropagated original clinical specimens using either conventional sequencing or pyrosequencing, suggesting that these variants were present in very low proportions (<10%) in clinical specimens and gained dominance after virus propagation in MDCK cells. All virus isolates recovered from the patient were resistant to adamantanes. Our findings highlight the potential for emergence and persistence of multidrug-resistant influenza viruses in oseltamivir-treated immunocompromised subjects and also highlight challenges for drug resistance diagnosis due to the genetic instability of the virus population upon propagation in cell culture.
引用
收藏
页码:1834 / 1841
页数:8
相关论文
共 40 条
[31]   Influenza virus proton channels [J].
Pinto, Lawrence H. ;
Lamb, Robert A. .
PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES, 2006, 5 (06) :629-632
[32]   FLUOROMETRIC ASSAY OF NEURAMINIDASE WITH A SODIUM (4-METHYLUMBELLIFERYL-ALPHA-D-N-ACETYLNEURAMINATE) SUBSTRATE [J].
POTIER, M ;
MAMELI, L ;
BELISLE, M ;
DALLAIRE, L ;
MELANCON, SB .
ANALYTICAL BIOCHEMISTRY, 1979, 94 (02) :287-296
[33]  
Schirmer P, 2009, EXPERT OPIN DRUG SAF, V8, P357, DOI [10.1517/14740330902840519, 10.1517/14740330902840519 ]
[34]   Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008 [J].
Sheu, Tiffany G. ;
Deyde, Varough M. ;
Okomo-Adhiambo, Margaret ;
Garten, Rebecca J. ;
Xu, Xiyan ;
Bright, Rick A. ;
Butler, Ebonee N. ;
Wallis, Teresa R. ;
Klimov, Alexander I. ;
Gubareva, Larisa V. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (09) :3284-3292
[35]  
Tisdale M, 2000, REV MED VIROL, V10, P45, DOI 10.1002/(SICI)1099-1654(200001/02)10:1<45::AID-RMV265>3.0.CO
[36]  
2-R
[37]   STRUCTURE OF THE INFLUENZA-VIRUS GLYCOPROTEIN ANTIGEN NEURAMINIDASE AT 2.9-A-RESOLUTION [J].
VARGHESE, JN ;
LAVER, WG ;
COLMAN, PM .
NATURE, 1983, 303 (5912) :35-40
[38]   Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient [J].
Weinstock, DM ;
Gubareva, LV ;
Zuccotti, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (09) :867-868
[39]   Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: Report of the neuraminidase inhibitor susceptibility network [J].
Wetherall, NT ;
Trivedi, T ;
Zeller, J ;
Hodges-Savola, C ;
McKimm-Breschkin, JL ;
Zambon, M ;
Hayden, FG .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (02) :742-750
[40]   Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility [J].
Yen, HL ;
Herlocher, LM ;
Hoffmann, E ;
Matrosovich, MN ;
Monto, AS ;
Webster, RG ;
Govorkova, EA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (10) :4075-4084